Aemetis (AMTX) Stock Forecast, Price & News

Aemetis (NASDAQ:AMTX) Frequently Asked Questions

Is Aemetis a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aemetis stock.
View analyst ratings for Aemetis or view top-rated stocks.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aemetis.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) released its quarterly earnings data on Thursday, March, 10th. The specialty chemicals company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.24. The specialty chemicals company earned $64.36 million during the quarter, compared to analysts' expectations of $55.87 million. During the same quarter in the prior year, the business posted ($0.68) EPS.
View Aemetis' earnings history.

What price target have analysts set for AMTX?

4 brokerages have issued twelve-month target prices for Aemetis' stock. Their forecasts range from $25.00 to $33.00. On average, they anticipate Aemetis' stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 298.2% from the stock's current price.
View analysts' price targets for Aemetis or view top-rated stocks among Wall Street analysts.

Who are Aemetis' key executives?

Aemetis' management team includes the following people:

• Mr. Eric A. McAfee, Co-Founder, Exec. Chairman & CEO (Age 59, Pay $410k)
• Mr. Todd A. Waltz, Exec. VP, CFO & Sec. (Age 61, Pay $335k) (LinkedIn Profile)
• Mr. Andrew B. Foster, Exec. VP & COO (Age 57, Pay $326.94k) (LinkedIn Profile)
• Mr. Sanjeev Gupta, Exec. VP (Age 62, Pay $341.14k)

Who are some of Aemetis' key competitors?

Some companies that are related to Aemetis include Origin Materials (ORGN), Westlake Chemical Partners (WLKP), Gevo (GEVO), Amyris (AMRS), Codexis (CDXS), REX American Resources (REX), Gores Holdings VIII (GIIX), FutureFuel (FF), Alto Ingredients (ALTO), Green Plains Partners (GPP), SolarWindow Technologies (WNDW), Wave Sync (WAYS), Image Chain Group (ICGL), American Energy Partners (AEPT) and Mace Security International (MACE).
View all of AMTX's competitors.

What other stocks do shareholders of Aemetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Tilly's (TLYS), Auxly Cannabis Group (CBWTF), Novan (NOVN), Aeterna Zentaris (AEZS), American Cannabis (AMMJ) and Bionano Genomics (BNGO).

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Who are Aemetis' major shareholders?

Aemetis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.05%), State Street Corp (5.86%), Vanguard Group Inc. (4.62%), Renaissance Technologies LLC (1.22%), Wellington Management Group LLP (1.12%) and Healthcare of Ontario Pension Plan Trust Fund (0.91%). Company insiders that own Aemetis stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Timothy Alan Simon and Todd Waltz.
View institutional ownership trends for Aemetis.

Which institutional investors are selling Aemetis stock?

AMTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cutler Group LP, UBS Group AG, Renaissance Technologies LLC, DAVENPORT & Co LLC, Simplex Trading LLC, Group One Trading L.P., and Russell Investments Group Ltd.. Company insiders that have sold Aemetis company stock in the last year include Andrew B Foster, Francis P Barton, John R Block, and Sanjeev Gupta.
View insider buying and selling activity for Aemetis or view top insider-selling stocks.

Which institutional investors are buying Aemetis stock?

AMTX stock was acquired by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, State Street Corp, BlackRock Inc., Jane Street Group LLC, Wellington Management Group LLP, Vanguard Group Inc., Baird Financial Group Inc., and L & S Advisors Inc.
View insider buying and selling activity for Aemetis or or view top insider-buying stocks.

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $7.45.

How much money does Aemetis make?

Aemetis has a market capitalization of $257.62 million and generates $211.95 million in revenue each year. The specialty chemicals company earns $-47.15 million in net income (profit) each year or ($1.460010) on an earnings per share basis.

How many employees does Aemetis have?

Aemetis employs 158 workers across the globe.

What is Aemetis' official website?

The official website for Aemetis is www.aemetis.com.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at [email protected], or via fax at 408-252-8044.